West Virginia University Logo

Disease Site: Lymphoma

8 protocol(s) meet the specified criteria

  • BMTCTN1101A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (haplo-BM) for Patients with Hematologic Malignancies
  • BO29561A Phase Ib/II Study Evaluating The Safety And Efficacy Of Obinutuzumab In Combination With Atezolizumab Plus Polatuzumab In Patients With Relapsed Or Refractory Follicular Lymphoma Or Diffuse Large B-Cell Lymphoma
  • CC-5013-NHL-008A Phase III Randomized Study of Lenalidomide Plus Rituximab Maintence Therapy Followed By Lenalidomide Single-Agent Maintenance versus Rituximab Maintenance in Subjects with Relapsed refractory Follicular, Marginal Zone or Mantle Cell Lymphoma
  • COG-AHOD1331AHOD1331 - A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
  • EAY131Molecular Analysis for Therapy Choice (MATCH)
  • MK-3475-013A Phase Ib Multi-Cohort Trial of MK-3475 (pembrolizumab) in Subjects with Hematologic Malignancies
  • MK3475-204Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkins Lymphoma
  • WVU11310Once daily intravenous Busulfex as part of reduced toxicity conditioning for patients with relapsed/refractory Hodgkin and non-Hodgkin lymphomas undergoing allogeneic hematopoietic cell transplantation - A multicenter phase II study